Loading...
Loading...
Browse all stories on DeepNewz
VisitJohnson & Johnson Acquires Rights to $1.25 Billion IL4RxIL31 Eczema Treatment
May 28, 2024, 02:55 PM
Johnson & Johnson announced on Tuesday that it has agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for approximately $1.25 billion. The treatment is a bispecific antibody designed to address atopic dermatitis by targeting two biological pathways associated with inflammation and itching. This acquisition marks Johnson & Johnson's second immunology deal this month, highlighting the company's strategic focus on expanding its immunology portfolio. The bispecific antibody, identified as IL4RxIL31, is in the clinical-stage and is expected to provide a novel approach to treating eczema.
View original story
Markets
Yes • 50%
No • 50%
Clinical trial registries or Johnson & Johnson's official updates
Yes • 50%
No • 50%
Johnson & Johnson's official communication or major healthcare news outlets
Yes • 50%
No • 50%
FDA announcements or Johnson & Johnson's official press releases
Equally effective as existing treatments • 25%
Ineffective • 25%
Less effective than existing treatments • 25%
More effective than existing treatments • 25%
Published results in peer-reviewed medical journals
Decrease in revenue • 25%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Johnson & Johnson's annual financial reports
No significant change in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
Significant increase in J&J stock price • 33%
Stock market data and analysis reports